Terminated PHASE3 INTERVENTIONAL 2-arm NCT05310071

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)

A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease

Sponsor: Biogen

Conditions Alzheimer's Disease

Interventions Aducanumab Placebo

Updated 22 times since 2022 Last updated: Apr 4, 2025 Started: Jun 2, 2022 Primary completion: Aug 12, 2024 Completion: Aug 12, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor's Decision

Other terminated trials from Biogen

See all terminations from Biogen

Other Alzheimer's Disease trials with similar outcome

Browse all Alzheimer's Disease trials

Listed as NCT05310071, this PHASE3 trial focuses on Alzheimer's Disease and remains terminated or withdrawn. Sponsored by Biogen, it has been updated 22 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

22 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
May 2025 — Sep 2025 [monthly]

Terminated PHASE3
Sep 2024 — May 2025 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 17 earlier versions

Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Sep 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE3
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE3

Phase: PHASE4 → PHASE3
Nov 2022 — Jan 2023 [monthly]

Recruiting PHASE4
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE4
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
May 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abington, United States , Albany, United States , Altamonte Springs, United States , Amherst, United States , Arzignano VI, Italy , Atlantis, United States , Atsugi-shi, Japan , Aurora, United States , Austin, United States , Bad Homburg, Germany and 212 more locations